Search

everythinglearnresearchcommunity

for

Search:↓

The user experienced side effects from oral finasteride and tried mixing it with liquid minoxidil but faced application issues. They are seeking a 5% minoxidil foam with a maximum of 0.15% topical finasteride concentration.

The user plans to switch from minoxidil to finasteride or dutasteride for hair loss, while managing hormones with aromatase inhibitors and SHBG blockers. They seek advice on the best options for these treatments, considering past side effects and future therapies.

A user stopped oral finasteride after 7 years due to decreased libido and switched to topical finasteride and minoxidil. Others shared similar experiences and discussed alternatives like dutasteride and topical treatments.

The conversation discusses using 1% cetirizine, an antihistamine, as a potential treatment for androgenetic alopecia (hair loss). One user plans to try cetirizine instead of finasteride, while others are curious or skeptical about its effectiveness, discussing the role of inflammation in hair loss.

OP is considering Bicalutamide for female AGA and TE but is concerned about its side effects and effectiveness compared to Finasteride. OP is also using Minoxidil and Spironolactone but is experiencing significant shedding and is unsure if it's androgen-driven or due to Minoxidil changes.

The conversation is about a transgender individual's experience with hair regrowth using topical minoxidil and hormone replacement therapy (HRT), expressing concern about the slow growth and thin appearance of their hair. Some responses encourage patience and highlight the variability of results, while others discuss the role of HRT and its effects.

The conversation discusses using non-denatured ethanol for RU58841. Treatments mentioned include Minoxidil, finasteride, and RU58841.

PP405 is being discussed as a potential hair loss treatment, possibly more effective than minoxidil. There are concerns about its effectiveness and product contamination, but some users report early signs of hair regrowth.

The conversation discusses managing gynecomastia symptoms potentially caused by finasteride use, with treatments including reducing finasteride dosage, using DIM, ashwagandha, tamoxifen, epistane, and arimistane. Users share experiences and advice on balancing testosterone and estrogen levels to address symptoms.

A user is considering making a 2% clascoterone lotion from powder due to unavailability in their location. They plan to mix clascoterone powder with retinol lotion and use literature to determine the correct dosage.

The discussion is about a hair loss drug called pyrilutamide. Users discuss its efficacy, safety, and expected market release around 2025-2026, with some expressing concerns about the authenticity of current market offerings.

Clascoterone cream was submitted for review to Health Canada in August 2022, with hopes of approval within 3-6 months. It may potentially enhance finasteride's effects for hair loss treatment.

A female user has experienced severe hair shedding since stopping birth control in late 2022, diagnosed as telogen effluvium with no signs of androgenetic alopecia. Despite healthy living and optimal bloodwork, she continues to shed hair daily but also sees significant regrowth.

The user has not seen results from various hair loss treatments including finasteride, dutasteride, minoxidil, and others over several years and is considering adding RU58841 and starting hormone replacement therapy. They are also experiencing anxiety and contemplating moving to a more accepting environment for their nonbinary identity.

The user increased their steroid dosage and noticed hair shedding, so they adjusted their regimen by reducing steroid doses and adding oral dutasteride. They are also experimenting with combining RU-58841 and KX-826/pyrilutamide in minoxidil to address hair loss.

The conversation discusses hair loss treatments, specifically mentioning pyrilutamide, minoxidil, and finasteride. The consensus suggests starting treatment early, with finasteride being a preferred option.

A user shared their positive experience with the telehealth service DocBright, highlighting its affordability and effectiveness in prescribing finasteride, oral minoxidil, and ketoconazole. They noted the service's unique ability to provide a prescription at age 17 but criticized the unprofessional communication with the dermatologist.

Hair loss treatments RU and topical spironolactone were compared. No specific results or conclusions were provided.

The conversation is about using a topical hair loss treatment from eSurgery containing finasteride, minoxidil, and tretinoin. The user is seeking recommendations and experiences with this specific product.

The conversation discusses the use of 12.5mg cyproterone every other day for hair loss. There's a concern about reducing testosterone potentially increasing DHT and negatively affecting hair.

The user is considering switching from topical minoxidil to a combined oral treatment of finasteride and minoxidil for better consistency but is concerned about potential side effects like shedding, dizziness, and swelling. Another user advises that oral minoxidil should only be used under medical supervision with regular health checks and suggests using reputable brands like Pfizer's Loniten.

A new topical finasteride has been approved in France, providing an alternative to oral finasteride with potentially fewer side effects. Users discuss the pros and cons of topical versus oral treatments, with some opting to create their own solutions to save money.

KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.

The conversation discusses the use of finasteride for hair loss, with OP considering switching to dutasteride due to concerns about effectiveness. Users share experiences and concerns about side effects, including potential impacts on fertility.

Users discussed the effectiveness of Everychem's solution, similar to PP405, with some reporting improved hair thickness and new growth. Concerns were raised about safety and the legitimacy of the product, with some users advising against purchasing research chemicals.

The user is struggling with seborrheic dermatitis and plans to try ciclopirox olamine after finding ketoconazole too drying. They are also using finasteride daily.

The user experiences irritation from alcohols in minoxidil and is considering alternatives like trichosol mixed with polyethylene glycol or DMSO. They seek advice on the best nonirritating option.

The user shared a one-year update on using oral finasteride (1.1 mg) and oral minoxidil (3 mg) along with ketoconazole shampoo, reporting significant hair regrowth and satisfaction with the results despite some side effects like thicker eyebrows and chest hair. The user encourages others to start treatment early and plans to continue the current regimen for further improvement.

The user has been using 0.25% topical finasteride for eight months with slight improvement and is considering switching to oral finasteride for convenience and potentially better results. Increasing the topical concentration to 0.33% or 0.5% is also an option, but oral finasteride may have more systemic side effects.

A dermatologist prescribed oral minoxidil, finasteride, and spironolactone, suggesting minoxidil and finasteride as the most effective combination, but with potential side effects. Another user recommended minoxidil (both topical and oral) and spironolactone for female hair loss, advising against finasteride.